Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Revenue (2016 - 2025)

Historic Revenue for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to $581000.0.

  • Sangamo Therapeutics' Revenue fell 9882.42% to $581000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $31.8 million, marking a year-over-year decrease of 3914.06%. This contributed to the annual value of $57.8 million for FY2024, which is 6720.23% down from last year.
  • According to the latest figures from Q3 2025, Sangamo Therapeutics' Revenue is $581000.0, which was down 9882.42% from $18.3 million recorded in Q2 2025.
  • Sangamo Therapeutics' 5-year Revenue high stood at $158.0 million for Q1 2023, and its period low was $356000.0 during Q2 2024.
  • Its 5-year average for Revenue is $25.1 million, with a median of $22.3 million in 2021.
  • As far as peak fluctuations go, Sangamo Therapeutics' Revenue crashed by 9969.55% in 2024, and later soared by 504213.48% in 2025.
  • Quarter analysis of 5 years shows Sangamo Therapeutics' Revenue stood at $28.6 million in 2021, then dropped by 4.67% to $27.2 million in 2022, then plummeted by 92.5% to $2.0 million in 2023, then surged by 218.32% to $6.5 million in 2024, then tumbled by 91.06% to $581000.0 in 2025.
  • Its Revenue stands at $581000.0 for Q3 2025, versus $18.3 million for Q2 2025 and $6.4 million for Q1 2025.